Merel Boer
Research Staff Other
Recent publications
Analysis and visualization of the course and burden over time of adverse drug reactions (ADRs) attributed to TNFα-inhibitors in patients with inflammatory rheumatic diseases (IRDs)
Merel de Boer, Helen R Gosselt, Jurriaan Jansen, Martijn B A van Doorn, Frank Hoentjen, Michael T Nurmohamed, Phyllis I Spuls, Sander W Tas, Harald E Vonkeman, Naomi T Jessurun
Expert Opinion on Drug Safety, 2023, vol. 22, p.195-202
The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung Cancer
Nikki de Rouw, Merel de Boer, René J Boosman, Michel M van den Heuvel, David M Burger, Joris E Lieverse, Hieronymus J Derijks, Geert W J Frederix, Rob Ter Heine
Clinical Pharmacology and Therapeutics, 2022, vol. 111, p.1103-1110
Kennis over beloop en belasting bijwerking nuttig voor patiënt en zorgverlener.
Merel de Boer, Helen R Gosselt, Jurriaan M Jansen, Phyllis I Spuls, Harald E Vonkeman, Sander W. Tas, Martijn B A van Doorn, Mike T Nurmohamed, Naomi Jessurun
Pharmaceutisch Weekblad, 2021, vol. 156, p.17-19
